Item 8.01 Other Events.

On January 4, 2021, Harpoon Therapeutics, Inc. (the "Company") issued a press release announcing that the first patient has been dosed with HPN328, a delta like ligand 3 ("DLL3")-targeting TriTAC®, in a Phase 1/2 clinical trial as an investigational treatment of small cell lung cancer and other tumors associated with DLL3 expression. A copy of the Company's press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits.




             Exhibit No.   Description

             99.1            Press release dated January 4, 2021.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses